News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Adaptive Biotechnologies insider Chad Robins has filed a Rule 144 notice to sell 278,676 shares of common stock, valued at $6.84 million, through Goldman Sachs & Co. LLC. This follows prior sales of 321,324 shares worth $7.96 million over the last three months. The …
A former officer of Adaptive Biotechnologies (ADPT), Harlan Robins, intends to sell 261,044 shares of common stock under Rule 144, valued at approximately $6.4 million. These shares were acquired as stock option compensation and will be sold via a cashless exercise and same-day sale …
John S. Montalbano, a director at AbCellera Biologics Inc. (NASDAQ:ABCL), purchased 10,000 common shares on August 18, 2026, at a price of $11.03 per share. This transaction, reported via a Form 4 filing, increases his direct ownership to 251,000 common shares, with an additional …
BridgeBio Pharma, Inc. recently completed a US$390 million equity offering and reported Q2 2026 revenues of US$243.68 million with a net loss of US$152.22 million. The company also highlighted new clinical data for Attruby and advanced its rare-disease pipeline with regulatory progress for BBP-418 …
The Rosen Law Firm is reminding purchasers of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) common stock during the Class Period (February 28, 2024, and February 25, 2026) of an important lead plaintiff deadline of September 22, 2026. The lawsuit alleges that PROCEPT made materially false …
Pacific Biosciences CEO Mark van Oene sold 26,911 shares of company stock for $30,409 on August 17, 2026. This transaction was primarily to cover tax withholding obligations associated with the vesting of restricted stock units. The sale occurred as PACB stock trades near its …
Pacific Biosciences of California (NASDAQ:PACB) insider Oene Mark Van sold 26,911 shares of the company's stock for approximately $30,409. The sale was primarily to cover tax withholding obligations related to vested equity awards, reducing his holdings by 0.98%. This transaction occurred as PACB shares …
Neurocrine Biosciences (NBIX) is potentially 28% undervalued according to a recent analysis, following positive KINECT-PRO Phase 4 results for its drug INGREZZA. Despite a recent share price dip, NBIX has shown strong long-term returns and has a diverse CNS pipeline, suggesting significant future growth …
Emergent BioSolutions reported strong Q2 financial results, exceeding revenue and profitability expectations primarily due to accelerated medical countermeasure deliveries. However, the company faces significant challenges in its naloxone franchise, leading to a substantial noncash impairment charge, lower full-year revenue and profitability guidance for 2026, …
5AM-affiliated funds and individuals have updated their beneficial ownership in Skye Bioscience (SKYE) and detailed a strategic merger with Redx Pharma Limited. Skye will acquire Redx shares through a UK Scheme of Arrangement, with Redx pre-transaction equity holders expected to own 46.17% of the …
PacBio (NASDAQ: PACB) CEO Mark Van Oene sold 26,911 shares of common stock on August 17, 2026, at a weighted average price between $1.13 and $1.15 per share. This sale was automatically conducted to cover tax withholding obligations associated with the vesting of restricted …
Pacira BioSciences insider Jonathan Slonin sold 3,040 shares of the company's stock for a total of $70,619.20. This transaction reduced his ownership by 1.39% to 216,384 shares and was executed under a pre-arranged Rule 10b5-1 trading plan. The company's stock traded up 3.3% to …
Benjamin Stone, Chief Business Officer of First Tracks Biotherapeutics, Inc. (NASDAQ: TRAX), was granted 60,492 performance stock units (PSUs) on August 15, 2026. This grant followed the certification of performance goals by the Compensation Committee. The PSUs will vest in two equal installments on …
Sana Biotechnology (SANA) recently reported narrower net losses for Q2 and H1 2026, leading to a recent positive shift in share price momentum. However, the company's Price-to-Book (P/B) ratio of 7x is significantly higher than the industry average, suggesting an overvalued status. Investors are …
BioXcel Therapeutics is facing an August 21 deadline to secure an acceptable transaction with its Oaktree-affiliated lenders, as its current cash reserves of $13.8 million are only sufficient to fund operations through August 2026. The company has severe liquidity issues, negative working capital, and …
Steven C. Crouse, President of Diagnostics and Spatial Biology at BIO-TECHNE Corp (NASDAQ:TECH), filed a Form 4 detailing stock transactions on August 18, 2026. The filing reported the vesting of 5,423 restricted stock units (RSUs) and the withholding of 1,947 shares at $72.4 per …
Larry L. Wood, the President and CEO of Procept BioRobotics Corporation (NASDAQ:PRCT), reported an indirect purchase of 23,900 shares of common stock on August 7, 2026. SEC Form 4 filing. Transaction summary Metric Value Transaction value ~$498,000 Post-transaction value $6.9 million Post-transaction shares (directly …
BridgeBio Pharma, Inc. CEO Neil Kumar had 71,217 Restricted Stock Units (RSUs) convert into common stock on August 16, 2026. To cover tax obligations from this vesting, 36,237 shares were withheld at $79.86 per share. Following these transactions, Kumar's indirect holdings across various trusts …
Adaptive Biotechnologies (ADPT) director Robert M. Hershberg has filed a Form 144 notice to potentially resell up to 30,664 shares of common stock. The proposed sale has an aggregate market value of $748,303.36 and includes shares from a stock option exercise and restricted stock. …
Search by ticker symbol or company name and select a result to open its chart. The US only control limits results to active US-listed stocks and ETFs.
Showing active US-listed stocks and ETFs only.